{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:15:02Z","timestamp":1788308102604,"version":"build-2803163510"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the effect that paliperidone palmitate 6-month long-acting injectable formulation (PP6M) had on metabolic parameters including body weight (BW), and blood lipid profiles, a post-hoc analysis was conducted to assess changes in BW from baseline to the end of study based on age, body mass index (BMI), and changes in blood lipid profiles during a 12-month, phase 3, double-blind (DB) clinical study. Long term effects of PP6M on BW and BMI were further explored during a 24-month extension study in which participants were treated exclusively with PP6M.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>In the 12-month DB phase, participants were randomized to receive PP6M or paliperidone palmitate 3-month long-acting injectable formulation (PP3M). The mean change in BW and abnormal weight percent change from baseline were calculated at endpoint by age, gender, and BMI. Additionally, treatment-emergent shifts from baseline for the four key lipid parameters (fasting low density lipoprotein [LDL], fasting triglycerides [TG], fasting total cholesterol [TC], and fasting high density lipoprotein [HDL]) during DB were assessed. Following this study, participants were given the opportunity to transition to a 24-month extension study and be treated with PP6M. The mean change and percent change in BW, and the mean change in BMI from DB baseline to the end of the extension study (36\u00a0months total) were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participants who were treated with PP6M showed numerically less weight gain, BMI, waist circumference, and more weight decrease compared to PP3M group during 12-month DB phase, though the proportion of participants reporting an abnormal change (\u22657% change) in BW did not significantly differ between PP3M and PP6M. The weight differences were more pronounced in the younger age group (18-25\u00a0years) and those who were overweight (BMI: 25 to &amp;lt;30\u00a0kg\/m2. Numerical differences in favor of PP6M were found in fasting blood lipids (HDL, LDL, TG, and TC). The changes in BW and BMI over time remained consistent throughout the 24-month extension, favoring PP6M in each instance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This post-hoc analysis demonstrated that PP6M was comparable to PP3M in terms of metabolic parameters; however, it may have a beneficial effect on weight gain, especially in young patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Post-Hoc Analysis of Studies NCT03345342 and NCT04072575 (ClinicalTrials.gov).<\/jats:p>\n                    <jats:p>Significant outcomes The findings from this study have highlighted that participants who were treated with the 6-month long-acting injectable formulation of paliperidone exhibited less weight gain during treatment overall, and significantly less weight gain in adolescents and young adults. Importantly, this trend continued over the course of long-term treatment, regardless of age. Participants treated with the 6-month formulation also had fewer shifts in blood lipids outside of the normal range and had more favorable changes in body mass index and waist circumference. These results suggest that when considering metabolic dysregulation as a factor in choosing a long-acting injectable antipsychotic, the 6-month formulation is a viable alternative to the 3-month formulation, particularly in younger patients with schizophrenia. Limitations Because this is a post hoc analysis and the study was not powered to test weight and metabolic changes, most endpoints were summarized descriptively and the statistical test was limited to the main endpoint (abnormal percent weight gain and loss).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijnp\/pyag042","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:15:59Z","timestamp":1786706159000},"source":"Crossref","is-referenced-by-count":0,"title":["Weight and metabolic changes in patients with schizophrenia treated with paliperidone palmitate 6-month formulation versus paliperidone palmitate 3-month formulation: a post-hoc analysis"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1085-7430","authenticated-orcid":false,"given":"Mark","family":"Guirguis","sequence":"first","affiliation":[{"name":"Johnson & Johnson Innovative Medicine, LLC , Titusville, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7595-2286","authenticated-orcid":false,"given":"Robert Karl","family":"Knight","sequence":"additional","affiliation":[{"name":"Johnson & Johnson Innovative Medicine, LLC , Titusville, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-2925","authenticated-orcid":false,"given":"Panna","family":"Sanga","sequence":"additional","affiliation":[{"name":"Johnson & Johnson Innovative Medicine, LLC , Titusville, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9806-674X","authenticated-orcid":false,"given":"John","family":"Han","sequence":"additional","affiliation":[{"name":"Johnson & Johnson Innovative Medicine, LLC , Titusville, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1592-7656","authenticated-orcid":false,"given":"Silvana","family":"Galderisi","sequence":"additional","affiliation":[{"name":"University of Campania Luigi Vanvitelli , Naples,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"2026090119362064300_ref1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/j.2051-5545.2009.tb00199.x","article-title":"Metabolic syndrome in people with schizophrenia: a review [published correction appears in world psychiatry. 2011;10(1):78]","volume":"8","author":"De Hert","year":"2009","journal-title":"World Psychiatry"},{"key":"2026090119362064300_ref2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","article-title":"Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care","volume":"10","author":"De Hert","year":"2011","journal-title":"World Psychiatry"},{"key":"2026090119362064300_ref3","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","article-title":"Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the global burden of disease (GBD) 2019","volume":"28","author":"Solmi","year":"2023","journal-title":"Mol Psychiatry"},{"key":"2026090119362064300_ref4","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40263-023-01028-1","article-title":"Effectiveness and safety of switching from oral antipsychotics to once-monthly paliperidone palmitate (PP1M) in the management of schizophrenia: a systematic review and meta-analysis","volume":"37","author":"Li","year":"2023","journal-title":"CNS Drugs"},{"key":"2026090119362064300_ref5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.eurpsy.2014.11.013","article-title":"Changes in body mass and metabolic profiles in patients with first-episode schizophrenia treated for 12 months with a first-generation antipsychotic","volume":"30","author":"Chiliza","year":"2015","journal-title":"Eur Psychiatry"},{"key":"2026090119362064300_ref6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/YIC.0000000000000448","article-title":"Cardiovascular risk factors and metabolic syndrome in patients treated with long-acting injectables antipsychotics: a retrospective study","volume":"38","author":"De Carlo","year":"2023","journal-title":"Int Clin Psychopharmacol"},{"key":"2026090119362064300_ref7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejpsy.2022.01.002","article-title":"The association of metabolic syndrome and long acting injectable antipsychotics: a systematic review","volume":"36","author":"Nguyen","year":"2022","journal-title":"Eur J Psychiatry"},{"key":"2026090119362064300_ref8","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3389\/fpsyt.2018.00744","article-title":"Metabolic syndrome in psychotic disorder patients treated with oral and long-acting injected antipsychotics","volume":"9","author":"Ventriglio","year":"2019","journal-title":"Front Psychiatry"},{"key":"2026090119362064300_ref9","doi-asserted-by":"publisher","first-page":"e36889","DOI":"10.1371\/journal.pone.0036889","article-title":"Changes in body weight and psychotropic drugs: a systematic synthesis of the literature","volume":"7","author":"Dent","year":"2012","journal-title":"PLoS One"},{"key":"2026090119362064300_ref10","first-page":"S7","article-title":"Adverse metabolic effects associated with use of long acting antipyshoctic injections in the maintenance treatment of chronic schizophrenia","volume":"263","author":"Gloria","year":"2013","journal-title":"Eur Arch Psychiatry Clin Neruosci"},{"key":"2026090119362064300_ref11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hup.1225","article-title":"Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine","volume":"26","author":"McDonnell","year":"2011","journal-title":"Hum Psychopharmacol"},{"key":"2026090119362064300_ref12","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1177\/0269881110370505","article-title":"Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials","volume":"25","author":"Millen","year":"2011","journal-title":"J Psychopharmacol"},{"key":"2026090119362064300_ref13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/eip.13013","article-title":"Weight gain and metabolic screening in young people with early psychosis on long acting injectable antipsychotic medication (aripiprazole vs paliperidone)","volume":"15","author":"Shymko","year":"2021","journal-title":"Early Interv Psychiatry"},{"key":"2026090119362064300_ref14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1471-244X-14-52","article-title":"Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate","volume":"14","author":"Sliwa","year":"2014","journal-title":"BMC Psychiatry"},{"key":"2026090119362064300_ref15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"2026090119362064300_ref16","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22r14490","article-title":"Comparative effects of 11 antipsychotics on weight gain and metabolic function in patients with acute schizophrenia: a dose-response meta-analysis","volume":"84","author":"Sab\u00e9","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"2026090119362064300_ref17","doi-asserted-by":"publisher","first-page":"S271","DOI":"10.1016\/j.euroneuro.2020.09.353","article-title":"Prevalence of metabolic syndrome and cardiovascular alterations in a sample of chronic psychiatric outpatients treated with long-acting injectable antipsychotics","volume":"40","author":"Molteni","year":"2020","journal-title":"Eur Neuropsychopharmacol"},{"key":"2026090119362064300_ref18","doi-asserted-by":"publisher","first-page":"112606","DOI":"10.1016\/j.psychres.2019.112606","article-title":"Cardio-metabolic risk in individuals prescribed long-acting injectable antipsychotic medication","volume":"281","author":"Morell","year":"2019","journal-title":"Psychiatry Res"},{"key":"2026090119362064300_ref19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/24750573.2017.1414575","article-title":"A comparison of depot and oral atypical antipsychotics in terms of metabolic syndrome markers","volume":"28","author":"Aykut","year":"2018","journal-title":"Psychiatry Clin Psychopharmacol"},{"key":"2026090119362064300_ref20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12888-025-06493-0","article-title":"A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases","volume":"25","author":"Lou","year":"2025","journal-title":"BMC Psychiatry"},{"key":"2026090119362064300_ref21","doi-asserted-by":"publisher","first-page":"S506","DOI":"10.1016\/S0924-977X(15)30695-7","article-title":"Metabolic syndrome and functionality 2-year follow-up study of 33 outpatients with a mental disorder treatment with paliperidone palmitate","volume":"25","author":"Zarranz","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"2026090119362064300_ref22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1089\/cap.2018.0044","article-title":"Retrospective analysis of the effectiveness and tolerability of long-acting paliperidone palmitate antipsychotic in adolescent first-episode schizophrenia patients","volume":"29","author":"Petri\u0107","year":"2019","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2026090119362064300_ref23","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14110","article-title":"Daily dose effects of risperidone on weight and other metabolic parameters: a prospective cohort study","volume":"83","author":"Piras","year":"2022","journal-title":"J Clin Psychiatry"},{"key":"2026090119362064300_ref24","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1089\/cap.2014.0130","article-title":"Long-term safety of paliperidone extended release in adolescents with schizophrenia: an open-label, flexible dose study","volume":"25","author":"Savitz","year":"2015","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2026090119362064300_ref25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00213-013-2970-7","article-title":"A prospective open-label trial of paliperidone monotherapy for the treatment of bipolar spectrum disorders in children and adolescents","volume":"227","author":"Joshi","year":"2013","journal-title":"Psychopharmacology"},{"key":"2026090119362064300_ref26","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1093\/ijnp\/pyab071","article-title":"A randomized, double-blind, multicenter, noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia","volume":"25","author":"Najarian","year":"2022","journal-title":"Int J Neuropsychopharmacol"},{"key":"2026090119362064300_ref27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/ijnp\/pyad028","article-title":"Long-term efficacy and safety of paliperidone 6-month formulation: an open-label 2-year extension of a 1-year double-blind study in adult participants with schizophrenia","volume":"26","author":"Najarian","year":"2023","journal-title":"Int J Neuropsychopharmacol"},{"key":"2026090119362064300_ref28","author":"World Bank Group Gender Data Portal"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyag042\/70725458\/pyag042.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/29\/9\/pyag042\/70725458\/pyag042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/29\/9\/pyag042\/70725458\/pyag042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:36:28Z","timestamp":1788305788000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/doi\/10.1093\/ijnp\/pyag042\/8767256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyag042","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,20]]},"article-number":"pyag042"}}